ELTP Stock Overview
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and manufacture of oral, controlled-release products and generic pharmaceuticals.
Elite Pharmaceuticals, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.036|
|52 Week High||US$0.052|
|52 Week Low||US$0.023|
|1 Month Change||9.24%|
|3 Month Change||-2.30%|
|1 Year Change||3.00%|
|3 Year Change||-58.52%|
|5 Year Change||-59.94%|
|Change since IPO||-98.20%|
Recent News & Updates
|ELTP||US Pharmaceuticals||US Market|
Return vs Industry: ELTP underperformed the US Pharmaceuticals industry which returned 9.9% over the past year.
Return vs Market: ELTP exceeded the US Market which returned -18.5% over the past year.
|ELTP Average Weekly Movement||8.8%|
|Pharmaceuticals Industry Average Movement||10.8%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: ELTP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: ELTP's weekly volatility (9%) has been stable over the past year.
About the Company
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and manufacture of oral, controlled-release products and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases.
Elite Pharmaceuticals, Inc. Fundamentals Summary
|ELTP fundamental statistics|
Is ELTP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ELTP income statement (TTM)|
|Cost of Revenue||US$17.65m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.0064|
|Net Profit Margin||19.85%|
How did ELTP perform over the long term?See historical performance and comparison